Study Shows DecisionDx-Melanoma Provides Prognostic Information on Survival Outcomes

Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology &nbsp Data shows testing with DecisionDx®-Melanoma provided significant prognostic information regarding survival outcomes &nbsp FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovati..